SCYX Overview

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).

Wall Street analysts forecast SCYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCYX is3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SCYNEXIS Inc revenue for the last quarter amounts to 18.65M USD, increased 1808.50

SCYNEXIS Inc. EPS for the last quarter amounts to 0.24 USD, decreased -366.67

SCYNEXIS Inc (SCYX) has 18 emplpoyees as of April 20 2026.

Today SCYX has the market capitalization of 49.58M USD.